Analytical Data
-
基因名
PLAU/uPA
- Application
-
别名
PLAU; ATF; URK; UK; UP-A; Abbokinase; Urokinase-Type Plasminogen Activator
-
种属
Rat
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
P29598
-
表达区间
Ser17~Phe432
-
分子量
50kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of PLAU (plasminogen activator, urokinase) and its recombinant protein, uPA (urokinase-type plasminogen activator), is significant in the field of biochemistry and medical research due to its crucial role in fibrinolysis and tissue remodeling. UPA is a serine protease that converts plasminogen into plasmin, initiating the degradation of fibrin in blood clots, which is vital for normal hemostasis and wound healing. Dysregulation of uPA is implicated in various pathological conditions, including cancer metastasis, where increased uPA activity is associated with tumor invasion and poor prognosis. Research into the recombinant expression of uPA has enabled the production of this protein for therapeutic and diagnostic applications. Recombinant uPA can be utilized in targeted therapies for thrombotic disorders, as well as in understanding its mechanisms in cancer progression. The ability to produce uPA in a controlled manner through recombinant techniques enhances the potential for developing novel treatments and improving patient outcomes. Furthermore, studies assessing the interactions of uPA with other proteins in the plasminogen activation system continue to provide insights into its biological functions and therapeutic potential, making it a focal point of ongoing research in both vascular biology and oncology.
